{
    "nct_id": "NCT06162663",
    "official_title": "Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors",
    "inclusion_criteria": "* Adult post menopausal breast cancer survivors (female, > 18 years old)\n* current selective estrogen modulator or aromatase inhibitor use\n* at least 6 weeks beyond completion of definitive treatment for breast cancer\n* less than 5 years from time of diagnosis.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* less than 6-month life expectancy\n* current steroid use\n* severe depression or anxiety\n* severe hepatic impairment\n* concurrent use of moderate or strong CYP3A inhibitors\n* current receipt of hospice care\n* severe mental illness\n* current use of greater than 40 morphine milligram equivalents daily\n* diagnosis of obstructive sleep apnea, narcolepsy or other sleep related illness other than insomnia\n* pregnancy\n* treatment with alternate pharmacotherapy for insomnia at the time of trial initiation\n* menstrual cycle within the past year",
    "miscellaneous_criteria": ""
}